*Says total first phase investment will be 30 mn Sfr
* Says facility will be operational by mid-2011
ZURICH, May 15 (Reuters) - Swiss drugs industry supplier Lonza Group LONN.VX said on Friday it was building a new facility in Singapore to expand its cell therapy business.
Lonza said in a press release that the total investment for the first phase would be approximately 30 million Swiss francs ($27.03 million).
Construction is due to begin in early 2010 and the facility is expected to be operational by mid-2011, it added.
“The facility will operate with cutting-edge technologies and a skilled labor force, allowing it to readily meet the needs of a broad range of customers and address the growing global demand for Cell Therapies,” said Lonza CEO Stefan Borgas in a statement. ($1=1.110 Swiss Franc) (Reporting by Martin de Sa’Pinto; editing by Simon Jessop)